EMBELL: Sales fell 7% but margins and manufacturing surged, with no market recovery expected before 2025

About this update from Embellence Group Ab

Q3 2024 saw a 7% sales decline due to weak retail demand, but gross and EBITDA margins improved on a stronger product mix. Manufacturing nearly doubled sales, and year-to-date sales grew 5%. No market recovery is expected until 2025, but strategic shifts to hospitality and direct-to-consumer channels are progressing. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Embellence Group Ab